{
    "id": "yago_7308_2",
    "rank": 21,
    "data": {
        "url": "https://www.dana-farber.org/find-a-doctor/andrew-a-lane",
        "read_more_link": "",
        "language": "en",
        "title": "Andrew A. Lane, MD, PhD - Dana-Farber Cancer Institute",
        "top_image": "https://www.dana-farber.org/sites/default/files/favicon.ico",
        "meta_img": "https://www.dana-farber.org/sites/default/files/favicon.ico",
        "images": [
            "https://dfci.widen.net/content/110ca04f-81c4-49f9-8e22-28a6ce5b3d0d/web/DFCI%20Logo%20Lens%20Color-rgb.svg",
            "https://dfci.widen.net/content/ri9n147djk/web/nurse-practitioner-and-patient556x381.jpg?crop=yes&k=c&w=600&h=368&itok=d4Yi5_AR",
            "https://dfci.widen.net/content/htfmtrxnyd/web/healthy-raw-vegetables556x381.jpg?crop=yes&k=c&w=600&h=368&itok=IcqGg6fP",
            "https://dfci.widen.net/content/oxtykuypie/web/Maria-Luisa-Guerrera-Bing%20Center-Waldenstr%C3%B6ms-Macroglobulinemia?crop=yes&k=c&w=600&h=368&itok=OQoc7eAo",
            "https://dfci.widen.net/content/f8qik7fbpb/web/cpop-team?crop=yes&k=c&w=600&h=368&itok=POlIPQUu",
            "https://dfci.widen.net/content/ty10dsbqhz/web/Jimmy-Fund-Telethon?crop=yes&k=c&w=600&h=368&itok=8Cd5sQ2d",
            "https://dfci.widen.net/content/megjz0gzpk/web/kimmie-ng-and-patient556x381.jpg?crop=yes&k=c&w=600&h=368&itok=patrnNAo",
            "https://dfci.widen.net/content/110ca04f-81c4-49f9-8e22-28a6ce5b3d0d/web/DFCI%20Logo%20Lens%20Color-rgb.svg",
            "https://www.dana-farber.org/sites/default/files/providers/30001.jpg",
            "https://www.dana-farber.org/sites/default/files/providers/top-doctor-award.png",
            "https://www.dana-farber.org/sites/default/files/styles/location_listing_image_desktop/public/providers/location_avtar.png?itok=ftkJEpXC",
            "https://www.dana-farber.org/sites/default/files/styles/location_listing_image_desktop/public/providers/location_avtar.png?itok=ftkJEpXC",
            "https://dfci.widen.net/content/vygo2orgcr/web/andrew_lane_sog_7762_12566x487.jpg?crop=yes&k=c&w=392&h=275&itok=BxRiES3k 1x",
            "https://www.dana-farber.org/sites/default/files/styles/card_392x275_/public/uploadedimages/expressreleases/andrew_lane_sog_7762_12.jpg?itok=F64QnQT5 1x",
            "https://www.dana-farber.org/sites/default/files/styles/card_392x275_/public/uploadedImages/Newsroom/Press_Releases/2017/andrew-lane.jpg?itok=tooBH5VI 1x",
            "https://dfci.widen.net/content/b77baa3d-5752-4cb4-b5fa-a7a932a6d0bf/web/branded-main-nav-logo630x155.png",
            "https://dfci.widen.net/content/74dbf2d2-1d7d-42a1-ba0a-403d6a65b0e1/web/magnet_recognition_logo_pms_3278.png",
            "https://dfci.widen.net/content/336fa306-616e-4ea9-8e39-7d6fdcd303eb/web/compcancercenter_v_rgb_color_badge.png",
            "https://dfci.widen.net/content/f4982a29-b2d1-4858-acdc-41c69a51adcd/web/us-news-adult-badge-2024-2025-143x140.png",
            "https://dfci.widen.net/content/fd625301-4c6c-457c-833e-ecb73ab1c1cb/web/us-news-pediatric-badge-2023-2024.png",
            "https://dfci.widen.net/content/564abc40-3275-4121-b409-143db5df0262/web/nccn_logo_stacked-01.png",
            "https://dfci.widen.net/content/ec46f092-0d9a-4bab-8c94-9d4f247e7095/web/hms-affiliate-logo-250.png"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": "2024-05-08T12:00:00+00:00",
        "summary": "",
        "meta_description": "Andrew A. Lane, MD, PhD - Medical Oncology",
        "meta_lang": "en",
        "meta_favicon": "/sites/default/files/favicon.ico",
        "meta_site_name": "",
        "canonical_link": "https://www.dana-farber.org/find-a-doctor/andrew-a-lane",
        "text": "Organ involvement in adults with BPDCN is associated with sun exposure history, TET2 and RAS mutations, and survival. Blood Adv. 2024 Jun 11; 8(11):2803-2812. View in: Pubmed\n\nTargetable leukaemia dependency on noncanonical PI3K? signalling. Nature. 2024 Jun; 630(8015):198-205. View in: Pubmed\n\nLeukemia circulation kinetics revealed through blood exchange method. Commun Biol. 2024 Apr 20; 7(1):483. View in: Pubmed\n\nPivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study. Lancet Oncol. 2024 Mar; 25(3):388-399. View in: Pubmed\n\nTreatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations. Leuk Lymphoma. 2024 May; 65(5):548-559. View in: Pubmed\n\nPhase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia. Blood Adv. 2024 02 13; 8(3):591-602. View in: Pubmed\n\nTagraxofusp for blastic plasmacytoid dendritic cell neoplasm. Haematologica. 2024 Jan 01; 109(1):44-52. View in: Pubmed\n\nAMPK activation induces immunogenic cell death in AML. Blood Adv. 2023 12 26; 7(24):7585-7596. View in: Pubmed\n\nTargetable leukemia dependency on noncanonical PI3K? signaling. bioRxiv. 2023 Dec 15. View in: Pubmed\n\nCutaneous Manifestations of Myeloid Neoplasms Exhibit Broad and Divergent Morphologic and Immunophenotypic Features but Share Ancestral Clonal Mutations With Bone Marrow. Mod Pathol. 2024 Jan; 37(1):100352. View in: Pubmed\n\nDDX41: here, there…and everywhere. Blood. 2023 10 05; 142(14):1177-1178. View in: Pubmed\n\nDown syndrome and leukemia: from basic mechanisms to clinical advances. Haematologica. 2023 10 01; 108(10):2570-2581. View in: Pubmed\n\nEnhancing dendritic cells by inhibiting BCL2. Trends Cancer. 2023 12; 9(12):987-988. View in: Pubmed\n\nLeukemia circulation kinetics revealed through blood exchange method. bioRxiv. 2023 Sep 05. View in: Pubmed\n\nLoss of chromosome Y in primary tumors. Cell. 2023 Jun 22. View in: Pubmed\n\nGenomics of PDGFR-rearranged hypereosinophilic syndrome. Blood Adv. 2023 06 13; 7(11):2558-2563. View in: Pubmed\n\nUltraviolet radiation shapes dendritic cell leukaemia transformation in the skin. Nature. 2023 Jun; 618(7966):834-841. View in: Pubmed\n\nFalse-Negative Testing for FIP1L1::PDGFRA by Fluorescence in situ Hybridization Is a Frequent Cause of Diagnostic Delay. Acta Haematol. 2023; 146(4):316-321. View in: Pubmed\n\nExpanding the Immunophenotypic Spectrum of Neoplastic and Reactive Plasmacytoid Dendritic Cells. Am J Clin Pathol. 2023 05 02; 159(5):455-463. View in: Pubmed\n\nNorth American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need. Blood. 2023 02 09; 141(6):567-578. View in: Pubmed\n\nNovel use of acitretin for posttransplant Grover's disease and cutaneous graft versus host disease. JAAD Case Rep. 2023 Mar; 33:67-69. View in: Pubmed\n\nLong-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm. J Clin Oncol. 2022 09 10; 40(26):3032-3036. View in: Pubmed\n\nPeripheral blood CD3+ T-cell gene expression biomarkers correlate with clinical frailty in patients with haematological malignancies. Br J Haematol. 2022 10; 199(1):100-105. View in: Pubmed\n\nAssessing the Antimicrobial Properties of Copper-Iodide Doped Adhesives in an In vitro Caries Model: A Pilot Study. Contemp Clin Dent. 2022 Apr-Jun; 13(2):118-124. View in: Pubmed\n\nTreatment patterns and outcomes of patients with CNS involvement of blastic plasmacytoid dendritic cell neoplasm (BPDCN). Leuk Lymphoma. 2022 11; 63(11):2757-2759. View in: Pubmed\n\nExpansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse. J Clin Invest. 2022 06 01; 132(11). View in: Pubmed\n\nShared Clonal Origin of Multiple Histiocytic and Dendritic Neoplasms and Polycythemia Vera, Follicular Lymphoma in 1 Patient. Am J Dermatopathol. 2022 12 01; 44(12):929-932. View in: Pubmed\n\nCD123 and More: How to Target the Cell Surface of Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancers (Basel). 2022 May 03; 14(9). View in: Pubmed\n\nTargeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells. Nat Commun. 2022 04 28; 13(1):2228. View in: Pubmed\n\nOutcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax. Leuk Lymphoma. 2022 08; 63(8):1934-1941. View in: Pubmed\n\nSingle-Cell Multiomics Reveals Clonal T-Cell Expansions and Exhaustion in Blastic Plasmacytoid Dendritic Cell Neoplasm. Front Immunol. 2022; 13:809414. View in: Pubmed\n\nMitochondrial variant enrichment from high-throughput single-cell RNA sequencing resolves clonal populations. Nat Biotechnol. 2022 07; 40(7):1030-1034. View in: Pubmed\n\nAMPK-PERK axis represses oxidative metabolism and enhances apoptotic priming of mitochondria in acute myeloid leukemia. Cell Rep. 2022 01 04; 38(1):110197. View in: Pubmed\n\nSex-Biased ZRSR2 Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis. Cancer Discov. 2022 02; 12(2):522-541. View in: Pubmed\n\nSingle-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALL. Blood. 2021 05 06; 137(18):2463-2480. View in: Pubmed\n\nTargeting CD123 in AML. Clin Lymphoma Myeloma Leuk. 2020 09; 20 Suppl 1:S67-S68. View in: Pubmed\n\nEvidence for separate transformation to acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm from a shared ancestral hematopoietic clone. Leuk Lymphoma. 2020 09; 61(9):2258-2261. View in: Pubmed\n\nComprehensive metagenomic analysis of blastic plasmacytoid dendritic cell neoplasm. Blood Adv. 2020 03 24; 4(6):1006-1011. View in: Pubmed\n\nBlastic Plasmacytoid Dendritic Cell Neoplasm in 2020 and Beyond. Hematol Oncol Clin North Am. 2020 06; 34(3):xiii-xiv. View in: Pubmed\n\nNovel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm. Hematol Oncol Clin North Am. 2020 06; 34(3):589-600. View in: Pubmed\n\nChromatin accessibility promotes hematopoietic and leukemia stem cell activity. Nat Commun. 2020 03 16; 11(1):1406. View in: Pubmed\n\nDNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance. J Clin Invest. 2019 11 01; 129(11):5005-5019. View in: Pubmed\n\nTagraxofusp, the first CD123-targeted therapy and first targeted treatment for blastic plasmacytoid dendritic cell neoplasm. Expert Rev Clin Pharmacol. 2019 Oct; 12(10):941-946. View in: Pubmed\n\nMulticenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark. Blood. 2019 08 22; 134(8):678-687. View in: Pubmed\n\nBlastic Plasmacytoid Dendritic Cell Neoplasm-Current Insights. Clin Lymphoma Myeloma Leuk. 2019 09; 19(9):545-554. View in: Pubmed\n\nBlastic Plasmacytoid Dendritic Cell Neoplasm: First Case Report From Rwanda and Review of the Literature. J Glob Oncol. 2019 06; 5:1-6. View in: Pubmed\n\nNext-generation characterization of the Cancer Cell Line Encyclopedia. Nature. 2019 05; 569(7757):503-508. View in: Pubmed\n\nTagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm. N Engl J Med. 2019 04 25; 380(17):1628-1637. View in: Pubmed\n\nVulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy. Cell Res. 2019 06; 29(6):446-459. View in: Pubmed\n\nSingle-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity. Cell. 2019 03 07; 176(6):1265-1281.e24. View in: Pubmed\n\nMore on Blastic Plasmacytoid Dendritic-Cell Neoplasms. N Engl J Med. 2019 02 14; 380(7):695-6. View in: Pubmed\n\nImproving Aseptic Technique During the Treatment of Pediatric Septic Shock: A Comparison of 2 Rapid Fluid Delivery Methods. J Infus Nurs. 2019 Jan/Feb; 42(1):23-28. View in: Pubmed\n\nBlastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN-Increasing Exposure over Two Years Since Inception of a Disease-Specific Twitter Community. Curr Hematol Malig Rep. 2018 12; 13(6):581-587. View in: Pubmed\n\nTrisomy of a Down Syndrome Critical Region Globally Amplifies Transcription via HMGN1 Overexpression. Cell Rep. 2018 11 13; 25(7):1898-1911.e5. View in: Pubmed\n\nAnalysis of First-Year Twitter Metrics of a Rare Disease Community for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN. Curr Hematol Malig Rep. 2017 12; 12(6):592-597. View in: Pubmed\n\nMonogenic Hashimoto thyroiditis associated with a variant in the thyroglobulin (TG) gene. J Autoimmun. 2018 01; 86:116-119. View in: Pubmed\n\nMaternal iAMP21 acute lymphoblastic leukemia detected on prenatal cell-free DNA genetic screening. Blood Adv. 2017 Aug 22; 1(19):1491-1494. View in: Pubmed\n\nSingle-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. Science. 2017 04 21; 356(6335). View in: Pubmed\n\nBlastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax. Cancer Discov. 2017 02; 7(2):156-164. View in: Pubmed\n\nSocial Media and Internet Resources for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Curr Hematol Malig Rep. 2016 12; 11(6):462-467. View in: Pubmed\n\nTumor-suppressor genes that escape from X-inactivation contribute to cancer sex bias. Nat Genet. 2017 01; 49(1):10-16. View in: Pubmed\n\nThe Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 07 11; 30(1):183. View in: Pubmed\n\nThe Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 04 11; 29(4):574-586. View in: Pubmed\n\nActivity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. Cancer Cell. 2015 Jul 13; 28(1):29-41. View in: Pubmed\n\nOutcome of Isolated Premature Menarche: A Retrospective and Follow-Up Study. Horm Res Paediatr. 2015; 84(4):217-22. View in: Pubmed\n\nImpact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015 Jun; 21(6):1046-1053. View in: Pubmed\n\nMutations in G protein ß subunits promote transformation and kinase inhibitor resistance. Nat Med. 2015 Jan; 21(1):71-5. View in: Pubmed\n\nTransmembrane Inhibitor of RICTOR/mTORC2 in Hematopoietic Progenitors. Stem Cell Reports. 2014 Nov 11; 3(5):832-40. View in: Pubmed\n\nPhase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia. Biol Blood Marrow Transplant. 2014 Dec; 20(12):2042-8. View in: Pubmed\n\nTriplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation. Nat Genet. 2014 Jun; 46(6):618-23. View in: Pubmed\n\nA targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood. 2014 Feb 27; 123(9):1293-6. View in: Pubmed\n\nPutative RNA-splicing gene LUC7L2 on 7q34 represents a candidate gene in pathogenesis of myeloid malignancies. Blood Cancer J. 2013 May 24; 3:e117. View in: Pubmed\n\nLow frequency clonal mutations recoverable by deep sequencing in patients with aplastic anemia. Leukemia. 2013 Apr; 27(4):968-71. View in: Pubmed\n\nNext-generation cDNA screening for oncogene and resistance phenotypes. PLoS One. 2012; 7(11):e49201. View in: Pubmed\n\nGenetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J Exp Med. 2012 Feb 13; 209(2):259-73. View in: Pubmed\n\nRisk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant. Leuk Lymphoma. 2012 Jun; 53(6):1130-6. View in: Pubmed\n\nMolecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation. Cancer Discov. 2012 Jan; 2(1):47-55. View in: Pubmed\n\nHigh-dose chemotherapy with busulfan and cyclophosphamide and autologous stem cell rescue in patients with Hodgkin lymphoma. Leuk Lymphoma. 2011 Jul; 52(7):1363-6. View in: Pubmed\n\nStem cells and DNA damage: persist or perish? Cell. 2010 Aug 06; 142(3):360-2. View in: Pubmed\n\nA protease-resistant PML-RAR{alpha} has increased leukemogenic potential in a murine model of acute promyelocytic leukemia. Blood. 2010 Nov 04; 116(18):3604-10. View in: Pubmed\n\nvon Willebrand disease type 2N: uncovering a congenital bleeding disorder in a patient with hepatitis C, cirrhosis, and coagulopathy. Am J Hematol. 2010 Feb; 85(2):134-5. View in: Pubmed\n\nHistone deacetylase inhibitors in cancer therapy. J Clin Oncol. 2009 Nov 10; 27(32):5459-68. View in: Pubmed\n\nAcute myeloid leukemia in first complete remission: How do we select patients for allogeneic stem cell transplantation?. American Journal of Hematology/Oncology. 2009; 8(10):508-511. View in: Pubmed\n\nPathogenesis of acute promyelocytic leukemia [dissertation]. 2006. View in: Pubmed\n\nMurine acute promyelocytic leukemia cells can be recognized and cleared in vivo by adaptive immune mechanisms. Haematologica. 2005 Aug; 90(8):1042-9. View in: Pubmed\n\nNeutrophil elastase is important for PML-retinoic acid receptor alpha activities in early myeloid cells. Mol Cell Biol. 2005 Jan; 25(1):23-33. View in: Pubmed\n\nExpression profiling of murine acute promyelocytic leukemia cells reveals multiple model-dependent progression signatures. Mol Cell Biol. 2004 Dec; 24(24):10882-93. View in: Pubmed\n\nNeutrophil elastase cleaves PML-RARalpha and is important for the development of acute promyelocytic leukemia in mice. Cell. 2003 Oct 31; 115(3):305-18. View in: Pubmed\n\nEph receptors discriminate specific ligand oligomers to determine alternative signaling complexes, attachment, and assembly responses. Genes Dev. 1998 Mar 01; 12(5):667-78. View in: Pubmed"
    }
}